Jci_page_head_homepage_01 Jci_page_head_homepage_02
Julie K. Olson, J. Ludovic Croxford, Miriam. A. Calenoff, Mauro C. Dal Canto, Stephen D. Miller
Published in Volume 108, Issue 2
J Clin Invest. 2001; 108(2):311–318 doi:10.1172/JCI13032
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6

SJL mice infected with TMEV expressing a PLP139-151 molecular mimic from the protease IV protein of H. influenzae develop clinical disease associated with activation of PLP139-151–specific Th1 cells. Separate groups of mice (n = 8) were injected intracerebrally with 3 × 107 PFU of recombinant virus (PLP139-BeAn or HI-BeAn) or with wild-type BeAn (WT BeAn) and observed at varying times after infection for development of clinical signs (a). Clinical results are representative of two separate experiments. Spleen cells were harvested at 21 days PI and rechallenged with viral peptide (VP270-86), myelin peptides (PLP139-151, PLP178-191), or mimic peptide (HI574-586) and supernatants collected after 48 hours and measured for IFN-γ secretion by ELISA (b). *Responses statistically significant compared with PBS-stimulated wells; P ≤ 0.01.